Form 4: Esperion Therapeutics CFO Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan
Insider Transaction Report
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 7,229 shares of common stock at $1.152 per share on June 17, 2025, to satisfy tax obligations related to vested restricted stock units, as disclosed in a Form 4 filing.
Summary
- Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc. (ESPR), reported a sale of common stock.
- The transaction involved the disposition of 7,229 shares.
- The shares were sold at a price of $1.152 per share.
- The sale occurred on June 17, 2025.
- The purpose of the sale was to satisfy tax obligations on vested restricted stock units.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan.
- Following this transaction, Benjamin Halladay directly beneficially owns 474,473 shares of Esperion Therapeutics common stock.
- A Limited Power of Attorney, dated November 16, 2022, authorizes Sheldon Koenig and Benjamin Looker to execute and file SEC forms on behalf of Benjamin Halladay.
Sentiment
Score: 5
Explanation: The transaction is a routine sale to cover tax obligations on vested equity, which is a neutral event and does not indicate a positive or negative sentiment towards the company's prospects. The use of a 10b5-1 plan further reinforces its routine nature.
Positives
- The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on immediate insider information.
Risks
- The reporting person acknowledges that the attorneys-in-fact and the Company are not assuming the reporting person's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended.
- The reporting person agrees to indemnify the attorney-in-fact and the Company from any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.
Future Outlook
The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider transaction.
Industry Context
This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries when executives receive equity compensation. It does not provide insights into broader industry trends or competitive dynamics within the pharmaceutical or biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of SEC Filings | A Limited Power of Attorney was granted by Benjamin Halladay to Sheldon Koenig and Benjamin Looker, authorizing them to execute and file various SEC forms (Form ID, 3, 4, 5, Schedule 13D) on his behalf as an officer/director of Esperion Therapeutics, Inc. | November 16, 2022 | This streamlines the process for insider reporting compliance, ensuring timely and accurate filings by delegating the administrative task to designated attorneys-in-fact. It clarifies responsibilities regarding compliance with Section 16 and Regulation 13D-G, explicitly stating that the reporting person retains ultimate responsibility. |
Stakeholder Impact
- Shareholders: The sale of 7,229 shares by a CFO for tax purposes is a routine event and is unlikely to have a significant impact on the company's stock price or shareholder confidence, especially given the relatively small number of shares compared to total outstanding shares and the stated reason for the sale.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| November 16, 2022 | Date the Limited Power of Attorney was executed by Benjamin Halladay. |
| June 17, 2025 | Date of the common stock transaction (sale) by Benjamin Halladay. |
| June 18, 2025 | Date the Form 4 was signed by Sheldon L. Koenig, by power of attorney. |
Recommendation
holdKeywords
Esperion Therapeutics, ESPR, Form 4, Insider Trading, Stock Sale, Tax Obligation, Restricted Stock Units, RSU, Benjamin Halladay, Chief Financial Officer, CFO, SEC Filing, 10b5-1 Plan, Corporate Governance, Power of Attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.